<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878485</url>
  </required_header>
  <id_info>
    <org_study_id>201903023</org_study_id>
    <nct_id>NCT03878485</nct_id>
  </id_info>
  <brief_title>Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine</brief_title>
  <official_title>Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In light of the increasing experience with magnetic resonance image-guided radiotherapy&#xD;
      (MRgRT) and adaptive planning and advances in magnetic resonance (MR)-only planning, the&#xD;
      investigators propose here to evaluate the feasibility and safety of same-session MR-only&#xD;
      simulation and treatment with SMART for spinal metastases. Although spine SBRT is a&#xD;
      standard-of-care treatment modality, this expedited same-session MR-only simulation and&#xD;
      treatment with SMART workflow is novel. Previously, delivery of spine SBRT has typically&#xD;
      required several days from time of consultation to simulation and then 1-2 weeks from&#xD;
      simulation to the initiation of treatment. On this proposed study, patients will not undergo&#xD;
      computed tomography (CT) simulation and will instead have same-session MR-only simulation and&#xD;
      treatment planning, on-table, using SMART. In this manner, patients would initiate treatment&#xD;
      within just several days from the consult. Feasibility of the workflow will be defined as&#xD;
      successful delivery of the first fraction of same-session MRI-only simulation and treatment&#xD;
      with SMART on the first on-table attempt for at least 70% of patients. Patients will be&#xD;
      treated in five fractions over 1-2 weeks. Although the long-term goal will be to achieve a&#xD;
      significantly shortened time from consult to treatment as compared to traditional&#xD;
      stereotactic body radiation therapy (SBRT) using simulation, the present study will be driven&#xD;
      by short-term goals of workflow feasibility and safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Anticipated">October 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants to receive delivery of the first fraction of same-session MRI-only simulation and treatment with SMART on the first on-table attempt</measure>
    <time_frame>Completion of first fraction of treatment for all enrolled participants (estimated to be 24 months)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Oligometastases of the Spine</condition>
  <arm_group>
    <arm_group_label>Stereotactic MRI-guided Adaptive Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRIdian Linac System from ViewRay</intervention_name>
    <description>0.35T MRI combined with a linear accelerator&#xD;
This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy</description>
    <arm_group_label>Stereotactic MRI-guided Adaptive Radiotherapy</arm_group_label>
    <other_name>MR-linac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic MRI-guided Adaptive Radiotherapy</intervention_name>
    <description>-The MR-linac will be delivering the radiation</description>
    <arm_group_label>Stereotactic MRI-guided Adaptive Radiotherapy</arm_group_label>
    <other_name>SMART</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least one disease site deemed to be suitable for treatment with spine SBRT as per&#xD;
             radiation oncology evaluation.&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) â‰¥ 60.&#xD;
&#xD;
          -  Deemed medically fit for SBRT by treating physician&#xD;
&#xD;
          -  Diagnostic CT with images through the projected treatment area within six months prior&#xD;
             to enrollment.&#xD;
&#xD;
          -  Diagnostic PET/CT, CT, or MRI with images through the projected treatment area&#xD;
             obtained less than or equal to six weeks prior to enrollment.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB approved written informed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past history of radiotherapy within the projected treatment field to be treated by&#xD;
             MRI-guided SBRT&#xD;
&#xD;
          -  Medical contraindication to undergoing MR imaging.&#xD;
&#xD;
          -  Spine metastasis resulting in symptomatic spinal cord compression.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the treating radiation oncologist, renders&#xD;
             the patient unfit for SBRT.&#xD;
&#xD;
          -  Pregnant and/or breastfeeding. Women of childbearing potential must have a negative&#xD;
             pregnancy test within 14 days of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Henke, M.D., M.S.C.I.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Henke, M.D., M.S.C.I.</last_name>
    <phone>314-747-4405</phone>
    <email>henke.lauren@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Henke, M.D., M.S.C.I.</last_name>
      <phone>314-747-4405</phone>
      <email>henke.lauren@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Lauren Henke, M.D., M.S.C.I.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clifford G Robinson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soumon Rudra, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Green, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justin Park, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

